UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AB0494 Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar PK and PD Profiles in Japanese and Caucasian Healthy Volunteers

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1063-1064

2015

Volltextzugriff (PDF)

SAT0231 Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid arthritis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.976

2018

Volltextzugriff (PDF)

AB0506 Identification of a Gene Signature and Response Biomarkers in Circulating Leukocytes of RA Patients After Treatment with the JAK1-Selective Inhibitor Filgotinib (GLPG0634)

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1068-1068

2015

Volltextzugriff (PDF)

THU0236 Once-Daily Dosing of GLPG0634, a Selective JAK1 Inhibitor, is Supported by Its Active Metabolite

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A244-A245

2013

Volltextzugriff (PDF)

THU0138 Glpg0634m1, A Major Metabolite of the Jak1-Selective Inhibitor Glpg0634, is Also Jak1-Selective and Efficient in the Rat CIA Model

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.226-227

2014

Volltextzugriff (PDF)

THU0116 Biological Effects of the JAK1 Selective Inhibitor GLPG0634 on Inflammation Markers in Arthritic Mice

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A201-A202

2013

Volltextzugriff (PDF)

Involvement of CCAAT/enhancer-binding protein and nuclear factor-kappa B binding sites in interleukin-6 promoter inhibition by estrogens

Molecular endocrinology (Baltimore, Md.), 1996-06, Vol.10 (6), p.713-722

1996

Volltextzugriff (PDF)

P133 In vitro pharmacological profile of GLPG3667 suggests differentiation from the TYK2 inhibitors deucravacitinib and TAK-279 at their clinical dose regimens

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i427-i427

2024

Volltextzugriff (PDF)

AB0144 PHARMACOLOGICAL CHARACTERIZATION OF GLPG3667, A SELECTIVE TYK2 INHIBITOR, SUPPORTS DEVELOPMENT IN DERMATOMYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1251-1252

2023

Volltextzugriff (PDF)

OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.140-140

2020

Volltextzugriff (PDF)

FRI0285 FILGOTINIB TREATMENT RESULTS IN REDUCTION OF BIOMARKERS ASSOCIATED WITH DISEASE IN PATIENTS WITH ANKYLOSING SPONDYLITIS

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.730-731

2020

Volltextzugriff (PDF)

FRI0428 The JAK1-selective inhibitor, filgotinib, inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.648

2017

Volltextzugriff (PDF)

PTU-003 Filgotinib decreases inflammatory markers associated with endoscopic improvement in moderate to severely active crohn’s disease

Gut, 2018-06, Vol.67 (Suppl 1), p.A63

2018

Volltextzugriff (PDF)

P535 Effects of the Janus Kinase 1 (JAK1)-selective inhibitor filgotinib on circulating cytokines and whole-blood genes/pathways of patients with moderately to severely active Crohn’s disease (CD)

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S457-S458

2020

Volltextzugriff (PDF)

THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.281

2017

Volltextzugriff (PDF)

OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study

Gut, 2017-07, Vol.66 (Suppl 2), p.A25

2017

Volltextzugriff (PDF)

THU0182 Monotherapy with the jak1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.270

2017

Volltextzugriff (PDF)

P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S381-S381

2020

Volltextzugriff (PDF)

OP0161 The JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.118

2017

Volltextzugriff (PDF)

P643 Filgotinib decreases systemic and mucosal markers of inflammation that are associated with endoscopic improvement in moderately to severely active Crohn’s disease patients

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S435-S436

2018

Volltextzugriff (PDF)

Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF- B site

Nucleic acids research, 1997-06, Vol.25 (12), p.2424-2429

1997

Volltextzugriff (PDF)

OP033 Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S20-S21

2017

Volltextzugriff (PDF)

Protéines ras et promoteurs de rétroéléments : les liaisons dangereuses

Pathologie et biologie, 1994, Vol.42 (8), p.743-746

GALIEN, R

1994

Volltextzugriff (PDF)

P072 GLPG0634, the first selective JAK1 inhibitor, shows strong activity in the mouse DSS-colitis model

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S92-S92

2014

Volltextzugriff (PDF)

TIF1γ, a novel member of the transcriptional intermediary factor 1 family

Oncogene, 1999-02, Vol.18 (5), p.1209-1217

1999

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(49)
Tagungsberichte
(1)

Sprache

Englisch
(48)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(17)
Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Patients
(7)
Female
(6)
Rheumatoid Arthritis
(6)
Transfection
(6)
Biological And Medical Sciences
(5)
Male
(5)
Base Sequence
(4)
Janus Kinase
(4)
Molecular Sequence Data
(4)
Animals
(3)
Biomarkers
(3)
Cost-Benefit Analysis
(3)
Crohn's Disease
(3)
Cytokines
(3)
Dna-Binding Proteins - Metabolism
(3)
Fundamental And Applied Biological Sciences. Psychology
(3)
Gene Expression
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AB0494 Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar PK and PD Profiles in Japanese and Caucasian Healthy Volunteers

SAT0231 Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid arthritis

AB0506 Identification of a Gene Signature and Response Biomarkers in Circulating Leukocytes of RA Patients After Treatment with the JAK1-Selective Inhibitor Filgotinib (GLPG0634)

THU0236 Once-Daily Dosing of GLPG0634, a Selective JAK1 Inhibitor, is Supported by Its Active Metabolite

THU0138 Glpg0634m1, A Major Metabolite of the Jak1-Selective Inhibitor Glpg0634, is Also Jak1-Selective and Efficient in the Rat CIA Model

THU0116 Biological Effects of the JAK1 Selective Inhibitor GLPG0634 on Inflammation Markers in Arthritic Mice

Involvement of CCAAT/enhancer-binding protein and nuclear factor-kappa B binding sites in interleukin-6 promoter inhibition by estrogens

P133 In vitro pharmacological profile of GLPG3667 suggests differentiation from the TYK2 inhibitors deucravacitinib and TAK-279 at their clinical dose regimens

AB0144 PHARMACOLOGICAL CHARACTERIZATION OF GLPG3667, A SELECTIVE TYK2 INHIBITOR, SUPPORTS DEVELOPMENT IN DERMATOMYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS

OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS

FRI0285 FILGOTINIB TREATMENT RESULTS IN REDUCTION OF BIOMARKERS ASSOCIATED WITH DISEASE IN PATIENTS WITH ANKYLOSING SPONDYLITIS

FRI0428 The JAK1-selective inhibitor, filgotinib, inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model

PTU-003 Filgotinib decreases inflammatory markers associated with endoscopic improvement in moderate to severely active crohn’s disease

P535 Effects of the Janus Kinase 1 (JAK1)-selective inhibitor filgotinib on circulating cytokines and whole-blood genes/pathways of patients with moderately to severely active Crohn’s disease (CD)

THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients

OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study

THU0182 Monotherapy with the jak1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients

P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology

OP0161 The JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis

P643 Filgotinib decreases systemic and mucosal markers of inflammation that are associated with endoscopic improvement in moderately to severely active Crohn’s disease patients

Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF- B site

OP033 Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor

Protéines ras et promoteurs de rétroéléments : les liaisons dangereuses

P072 GLPG0634, the first selective JAK1 inhibitor, shows strong activity in the mouse DSS-colitis model

TIF1γ, a novel member of the transcriptional intermediary factor 1 family

Suchergebnisse filtern